Articles in this supplement focus on the global opioid crisis, including coverage of harm reduction approaches, health justice promotion, and lessons learned.
Breadcrumb
- Home
- Resources and Tools
Resources and Tools
The COVID-19 pandemic resulted in federal policy changes related to telehealth use that allowed states to maximize access to medications for opioid use disorder (MOUD) through telehealth.
Individuals who have HIV who also use drugs experience increased age-matched morbidity and mortality in comparison with those with HIV who do not use drugs.
This package is a learning tool designed for health departments and community-based organizations newly offering syringe services programs (SSPs) with the purpose of indexing the materials needed for safer injection, what to offer at a syringe services program, and how to explain what materials a
A recent study published in Drug and Alcohol Dependence found evidence for racial/ethnic disparities in buprenorphine distribution across the United States.
Transgender people and communities, including nonbinary people, have specific needs within harm reduction programs.
In recent years, the gap in the rate of opioid overdoses among Black and white Americans has narrowed significantly, with increases in Black mortality driven in part by the addition of synthetic opioids to other drugs.
Opioid agonist treatment (OAT) is the provision of medications (methadone and buprenorphine) that activate the opioid receptors to prevent withdrawal and reduce cravings for opioids.
This publication, part of SAMHSA's Evidence Based Resource Guide series, addresses the co-occurrence of HIV and mental illness and/or SUD.
This article describes how the HIV testing window period is a challenge related to prescribing PrEP for people who inject drugs, and discusses current approaches and how data are needed to help guide best practices.
Pagination
- Page 1
- Next page ››